Heberon® Alfa R (Oncology)
Recombinant interferon alpha-2b for oncology indications including hairy cell leukemia, Kaposi's sarcoma and malignant melanoma.
Product information
Recombinant interferon alpha-2b for oncology use. Developed by CIGB, Havana. Registered in 40+ countries.
Indications
Hairy cell leukemia, AIDS-related Kaposi's sarcoma, malignant melanoma and other oncology indications.
Formulation
Injectable recombinant human interferon alpha-2b solution.
Administration
Subcutaneous or intramuscular injection, as prescribed by oncology specialist.
Precautions
Monitor for flu-like symptoms, cytopenias, depression and hepatic function. Use under oncology supervision.
Product information
- Manufacturer
- CIGB, Havana
- Regulatory status
- Registered in 40+ countries
Cancer & Oncology
CIMAvax-EGF®
Therapeutic vaccine targeting the EGF pathway for non-small cell lung cancer — registered in multiple countries.
VAXIRA® (Racotumomab)
Monoclonal antibody vaccine targeting NeuGcGM3 ganglioside antigens expressed on lung tumors.
HEBERSaVax®
Cuban biotech oncology product under investigation for cancer immunotherapy.